Published in:
Open Access
01-12-2012 | Review
Current management and novel agents for malignant melanoma
Authors:
Byung Lee, Nikhil Mukhi, Delong Liu
Published in:
Journal of Hematology & Oncology
|
Issue 1/2012
Login to get access
Abstract
Advanced malignant melanoma remains a challenging cancer. Over the past year, there have been 3 agents approved for treatment of melanoma by Food and Drug Administration. These include pegylated interferon alpha-2b for stage III melanoma, vemurafenib for unresectable or metastatic melanoma with BRAF V600E mutation, and ipilimumab for treatment of unresectable or metastatic melanoma. This review will also update on the development of novel agents, including tyrosine kinase inhibitors and adoptive cellular therapy.